Allogene Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 233
- Market Cap
- $560.4M
- Website
- http://www.allogene.com
- Introduction
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Foresight Diagnostics Provides 2025 Outlook and 2024 Year in Review
Foresight Diagnostics achieved 100% revenue growth, secured FDA IDE approval for Foresight CLARITY™ in ALPHA3 trial, and plans for 2025 include expanding biopharma partnerships, commercializing Foresight CLARITY™ in lymphoma, and establishing LDT for solid tumors. Highlights include doubling revenue, strategic partnerships, and advancements in MRD detection technology.
Leveling Up: Cell Therapy Research Expands Horizons in Autoimmune Disease
Cell therapy, particularly CAR-T, is advancing in treating autoimmune diseases, showing promise in early trials for conditions like lupus. Despite no approvals yet, its potential for curative effects excites the field. Companies like Kyverna, Cabaletta, and Cartesian are leading research, with some patients experiencing life-changing results. However, experts caution about overhyping, emphasizing the need for long-term data and recognizing that cell therapy won't work for all patients.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
2024 mixed for biotech; sector down 14% due to Q3 results, guidance cuts, pipeline setbacks, and vaccine skeptic nominee. Despite challenges, biotech remains attractive for innovation and M&A activity. Recommended stocks: Allogene Therapeutics (ALLO), Rezolute (RZLT), Vanda Pharmaceuticals (VNDA), all under $10 with strong Zacks Rank and ABR.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
The biotech sector in 2024 saw initial gains erased by setbacks, yet attracted investors with innovations in obesity, immunology, and gene therapy. Immunocore Holdings, Allogene Therapeutics, and Day One Biopharmaceuticals, despite stock declines, are poised for recovery in 2025 due to anticipated regulatory approvals and pipeline progress.
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
Allogene Therapeutics mourns the passing of founding board member David Bonderman, a champion of CAR T therapy and a mentor to the company. His contributions were pivotal in guiding Allogene's development of AlloCAR T™ products for cancer and autoimmune diseases.
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
Alnylam Pharmaceuticals' sNDA for Amvuttra (vutrisiran) to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM) has been accepted by the FDA under Priority Review, with a decision expected by March 23, 2025. Supported by positive phase III HELIOS-B study results, vutrisiran could become the first therapeutic approved in the U.S. for both hATTR polyneuropathy and ATTR-CM. Amvuttra sales significantly contribute to Alnylam's revenue, with potential for substantial growth upon approval.
CAR T-cell Therapy Strategic Business Research Report 2024
The global CAR T-cell therapy market is projected to grow from $2.7B in 2023 to $10.8B by 2030, driven by tech advancements, expanding clinical applications, and rising cancer prevalence. Key trends include the move into solid tumors and development of allogeneic therapies, though challenges like side effects and high costs persist.
CAR T-cell Therapy Strategic Business Research Report 2024: Global Market to Reach $10.8 Billion by 2030 - Expanding Clinical Applications Beyond Blood Cancers Expands Opportunities
The global CAR T-cell therapy market, valued at US$2.7 billion in 2023, is projected to grow to US$10.8 billion by 2030, driven by technological advancements, expanding clinical applications, and the demand for personalized cancer treatments. Key growth areas include treatment for solid tumors and allogeneic therapies, despite challenges like high costs and side effects.
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma
DelveInsight's follicular lymphoma pipeline report highlights 50+ companies developing 55+ therapies, including key players like Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, and others. Promising therapies such as Parsaclisib, TQ-B3525, and Tafasitamab are in various clinical trial phases. Notable events include Incyte's acquisition of tafasitamab rights and Janssen's collaboration with CBMG for CAR-T therapies.
© Copyright 2025. All Rights Reserved by MedPath